Merus and Gilead Enter into a Research Collaboration, Option & License Agreement to Discover of Antibody-Based Trispecific T-Cell Engagers
Shots:
- The collaboration will combine Gilead's oncology expertise & Merus' Triclonics platform to discover novel dual TAA targeting trispecific Abs. The latter will handle early-stage research activities
- Merus obtains $56M upfront for initial targets in cash & $25M as equity investment, ~$1.5B incl. near term & option payments as well as milestones for development & commercialization plus mid-single to low-double digits sales-based tiered royalties. It gets an option to pursue a 3rd, allowing a 50/50 split of net profits & losses instead of future milestones & royalties
- Gilead gets right to license the developed programs after research activities & will handle their additional research, development & commercialization on exercising the option
Ref: Merus | Image: Gilead
Related News:- Merus’ Zenocutuzumab Receives the US FDA’s Breakthrough Therapy Designation for NRG1 Fusion Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
